Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
SHSE:688513'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03 Med: 0.33 Max: 0.7
Current: 0.52
During the past 9 years, the highest Debt-to-EBITDA Ratio of Chengdu Easton Biopharmaceuticals Co was 0.70. The lowest was 0.03. And the median was 0.33.
SHSE:688513's Debt-to-EBITDA is ranked better than 65.79% of 304
companies
in the Biotechnology industry
Industry Median: 1.215
vs SHSE:688513: 0.52
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Chengdu Easton Biopharmaceuticals Co Debt-to-EBITDA Related Terms
Chengdu Easton Biopharmaceuticals Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Debt-to-EBITDA Chart
SHSE:688513 vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Debt-to-EBITDA of 0.52 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chengdu Easton Biopharmaceuticals Co. This is 58% above median its historical median of 0.33. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Debt-to-EBITDA has ranged from 0.03 to 0.70. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #104 out of 304 companies in the Biotechnology industry, placing it in the top 34.2%.
Is Chengdu Easton Biopharmaceuticals Co's Debt-to-EBITDA too high?
Chengdu Easton Biopharmaceuticals Co's current Debt-to-EBITDA of 0.52 is 58% above median its 10-year median of 0.33. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.70. The Biotechnology industry median Debt-to-EBITDA is 1.22. Chengdu Easton Biopharmaceuticals Co's value of 0.52 is 57.2% below this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #104 out of 304 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #104 out of 304 companies for Debt-to-EBITDA. This puts Chengdu Easton Biopharmaceuticals Co in the upper half of its industry. The industry median Debt-to-EBITDA is 1.22. Chengdu Easton Biopharmaceuticals Co's value of 0.52 is 57.2% below this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own Debt-to-EBITDA has ranged from 0.03 to 0.70 over the past decade. While the company's 10-year median is 0.33 vs. the industry median of 1.22, Chengdu Easton Biopharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.22, based on 304 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current Debt-to-EBITDA of 0.52 is 57.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Chengdu Easton Biopharmaceuticals Co. For the Biotechnology industry, the median Debt-to-EBITDA is 1.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current Debt-to-EBITDA is 0.52, which is 58% above median its own 10-year median of 0.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Fairly Valued. The stock's GF Value™ is ¥46.19, compared to a current price of ¥47.14 — trading 2.1% above its estimated fair value. The current Debt-to-EBITDA is 0.52, which is 58% above median its 10-year median of 0.33 and 57.2% below the Biotechnology industry median of 1.22. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Debt-to-EBITDA is 0.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥47.14 is trading 2.1% above its estimated GF Value™ of ¥46.19.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Fairly Valued.
Key valuation signals for SHSE:688513:
Debt-to-EBITDA: 0.52 (58% above median its 10-year median of 0.33)
GF Value™: ¥46.19 vs. price of ¥47.14 (2.1% above fair value)
Industry Position: 57.2% below the Biotechnology median (#104 of 304)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
91GF Score
Get the complete analysis for SHSE:688513
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
